Where the money goes: UK funding to build a supply of insulin-making cells
Diabetes UK reported investing 4.2m pounds across 21 projects in 2025, including UK teams building a supply of stem-cell-derived insulin-making cells.
A cure for Type 1 is not here, and nothing below changes your day. What did happen in 2025 is that Diabetes UK put 4.2 million pounds into 21 research projects, and some of it targets a quiet bottleneck behind every cell cure: actually making enough insulin-making cells to treat people.
- Beta cells are the pancreas cells that make insulin, and in Type 1 the immune system has destroyed most of them.
- A future cell cure would replace them, but a real hurdle is making enough good cells for everyone who needs them.
- This UK money helps build a dependable supply of insulin-making cells grown from stem cells (starter cells that can become other types).
- It is early groundwork, not a trial to join or a treatment this year, and your own care carries on unchanged.
What Diabetes UK actually funded
In January 2026, Diabetes UK reported its 2025 research spending: 4.2 million pounds spread across 21 projects. That money covers a lot of ground, from everyday life with diabetes to the long-shot science of replacing insulin-making cells. One strand pays for UK teams to build a dependable supply of beta cells grown from stem cells. In plain terms, that means a steady stock of lab-grown insulin-making cells that researchers around the country can draw on, instead of every team having to make their own from scratch each time.
Why a supply problem, not a headline
You have probably seen cure stories that promise the world and then go quiet. Here is the honest version of this one. Before transplanted cells can ever become a treatment, someone has to make them in large amounts, to the same quality every time, and safely enough to put into a person. That manufacturing problem is unglamorous, and it is one of the real reasons cures stay years away. Paying for it is sensible groundwork. It is not a clinical trial, not a product, and not something that reaches a UK clinic soon. Think of it as laying track, well before any train arrives.